B

Bio Clinical Trial Interpreter

3.25

Derivation Chain

Step 1 Novo Nordisk's disappointing drug results trigger stock crash
→
Step 2 Biotech investors struggle to interpret clinical data
→
Step 3 Service that summarizes English clinical trial results in Korean from an investment perspective

Problem

Over 80% of domestic biotech/pharma individual investors cannot directly interpret English clinical trial results (phase outcomes, endpoint achievement, p-values, hazard ratios) and rely on brokerage Reports or community interpretations. Brokerage reports take 1–3 days to publish, and community interpretations are frequently inaccurate, leading to an average 5–10% investment loss from poor decisions.

Solution

Paste a ClinicalTrials.gov or pharma press release URL to receive a Korean-language translation of clinical results within 30 seconds, with key metrics highlighted (efficacy, side effects, statistical significance) and investment-perspective analysis (competitive positioning vs. rival drugs, approval probability, stock price impact scenarios).

Target: Individual biotech/pharma stock investors (ages 30–50), investment community operators, small investment advisory firms
Revenue Model: Premium: 3 free analyses/month; unlimited + real-time alerts + automatic portfolio stock analysis at $37/month
Ecosystem Role: Education
MVP Estimate: 2_weeks

NUMR-V Scores

N Novelty
3.0/5
U Urgency
3.0/5
M Market
2.0/5
R Realizability
5.0/5
V Validation
2.0/5
NUMR-V Scoring System
N Novelty1-5How uncommon the service is in market context.
U Urgency1-5How urgently users need this problem solved now.
M Market1-5Market size and growth potential from proxy indicators.
R Realizability1-5Buildability for a small team with realistic constraints.
V Validation1-5Validation signal quality from competition and demand data.
Each dimension is scored 1-5 and weighted into grade S/A/B/C/D.
SaaS N=.15 U=.20 M=.15 R=.30 V=.20 Senior N=.25 U=.25 M=.05 R=.30 V=.15

Feasibility (77%)

Tech Complexity
34.7/40
Data Availability
22.5/25
MVP Timeline
20.0/20
API Bonus
0.0/15
Feasibility Breakdown
Tech Complexity/ 40Difficulty of core implementation stack.
Data Availability/ 25Practical availability and cost of required data.
MVP Timeline/ 20Expected time to ship a usable MVP.
API Bonus/ 15Bonus for viable public API leverage.
Total 100 points; below 50% is filtered out.

Market Validation (50/100)

Competition
8.0/20
Market Demand
6.2/20
Timing
14.0/20
Revenue Signals
7.5/15
Pick-Axe Fit
7.5/15
Solo Buildability
7.0/10
Validation Breakdown
Competition/ 20Signal quality from competitor landscape.
Market Demand/ 20Demand proxies from search and mention patterns.
Timing/ 20Fit with current shifts in tech, behavior, and regulation.
Revenue Signals/ 15Reference evidence for monetization viability.
Pick-Axe Fit/ 15How well the concept serves participants in a trend.
Solo Buildability/ 10Practicality for lean-team implementation.
Total 100 points; below 50 is filtered out.

Technical Requirements

AI/ML [medium] Backend [low] Frontend [low]
Dashboard